Tonix Pharmaceuticals Reports Q2 Revenue Surge as TONMYA Sales Reach $11 Million, Signaling Strong Market Adoption

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. The surge was primarily driven by approximately $11 million in net sales of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company's recently approved treatment for fibromyalgia. This marks a significant milestone for Tonix as it transitions into a commercial-stage biotechnology company.

During the quarter, TONMYA recorded 12,592 total prescriptions, a 100% sequential increase. New patient prescriptions rose 36%, while refills surged 207%, indicating strong patient and physician adoption. The drug currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. Coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This broadening access is likely to further accelerate sales growth.

The company's strong commercial performance is complemented by a robust pipeline. Tonix has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). This study is a key step in expanding the use of cyclobenzaprine-based therapies beyond fibromyalgia. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. This candidate addresses a significant unmet medical need, as Lyme disease affects hundreds of thousands of people annually.

Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This runway provides the company with the financial stability to advance its pipeline and support the commercial launch of TONMYA.

The implications of this announcement are profound for Tonix and the broader biotech sector. TONMYA's strong launch numbers demonstrate that there is a significant market for new fibromyalgia treatments, which have been limited for over 15 years. The rapid uptake in prescriptions and refills suggests that patients and physicians are eager for effective therapies, and TONMYA is meeting that demand. The expansion of insurance coverage will likely drive further revenue growth, positioning Tonix for sustained commercial success.

Moreover, the progress in the pipeline, particularly the Phase 2 HORIZON study for MDD, highlights the potential of TNX-102 SL to address another high-unmet-need CNS condition. If successful, this could diversify Tonix's revenue streams and reduce reliance on a single product. The Lyme disease prophylaxis candidate TNX-4800 also represents a novel approach to prevention, potentially opening a new market for the company.

Investors and industry observers will be watching closely as Tonix continues to execute on its commercial and clinical strategies. The company's ability to generate significant revenue from TONMYA while advancing multiple pipeline programs underscores its position as a key player in CNS and immunology. For more information on Tonix Pharmaceuticals, visit their newsroom at https://nnw.fm/TNXP.